Thu, 06/11/2020 - 16:20
Cannabis Used to Treat Inflammatory and Pruritic Conditions
A research group out of Washington state presented their findings on cannabis use among dermatology patients at the AAD VMX 2020.
Patients With Alopecia Using More Supplements Per Day, Study Finds
Findings from a recent poster abstract highlighted the the amount of supplements patients with alopecia would take in a day compared with the general population.
Baricitinib Improves Itch, QoL for Patients with Atopic Dermatitis

As an oral selective inhibitor of Januse kinase (JAK) 1 and JAK 2, which may play a role in the inflammatory response of atopic dermati

Type A Botulinum Toxin Study Demonstrates Safety in Clinical Research for Naïve and Treatment-experienced Patients

Glabellar lines are one of the most commonly requested sites for neuromodulator injection, and clinical trials for a new type A botulin

acne
Once-Daily Tazarotene Formula 0.045% Effective for Moderate to Severe Acne

Researchers have found that once-daily tazarotene 0.045% is efficacious with a favorable safety and tolerability profile for the treatm

Trial Results Show Efficacy, Safety, Durability of Bimekizumab
Data on the efficacy and safety of bimekizumab from 2 phase 3 clinical trials presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for the treatment of moderate to severe plaque psoriasis.
A Virtual Experience for the Modern Dermatologist
To meet the educational needs and plenary requirements normally fulfilled by its in-person event, the Academy announced the AAD Virtual Meeting Experience (VMX), set to take place June 12 to June 14, 2020.
Back to Top